Why is PERNIXOL® different?
PERNIXOL® stands out from other joint supplements through its concentrated liquid formula, marine Omega-3s and New Zealand green-lipped mussel oil.
Pauline Durepaire
Published in
PERNIXOL® DailyMany joint supplements for dogs look alike. They all promise to support mobility, relieve discomfort, or help ageing joints. Yet when you look closer, they are not all equal.
When it comes to joint support, promises matter less than objective criteria: the form of the supplement, the actual concentration of active ingredients, their bioavailability, the quality of their sources and, above all, the scientific evidence available in dogs.
It is precisely on these points that PERNIXOL® stands out.
Developed by Laboratoire Sensilia, PERNIXOL® was designed as a premium marine solution, based on distinctive, well-documented active ingredients: the Omega-3 fatty acids EPA and DHA from New Zealand green-lipped mussel oil and fermented microalgae.
This article examines what distinguishes PERNIXOL® from other joint supplements, why its formulation is different and which objective criteria can help you make an informed choice to support your dog's mobility over the long term.
What truly sets an effective joint supplement apart
When looking for a joint supplement for your dog, you are quickly faced with a wide range of formulas containing ingredients such as glucosamine, collagen, botanical extracts, green-lipped mussel and Omega-3s.
On paper, everything seems promising. But in reality, not all active ingredients are supported by the same level of evidence in dogs, and this is often what distinguishes a well-formulated supplement from a product driven primarily by marketing.
To make a rational choice, you need to look at three essential criteria:
scientific evidence, form, and dosage.
Very popular ingredients… but not always effective
Many joint supplements for dogs rely on ingredients that have become extremely common, including glucosamine, chondroitin, collagen, devil's claw and turmeric.
The problem is that their popularity often exceeds their real effectiveness.
- Glucosamine and chondroitin: despite their ubiquity, several clinical trials have not shown a significant difference compared with placebo in arthritic dogs. Their bioavailability is also low, which limits their practical interest.
- Collagen: some encouraging findings have been reported, but results remain heterogeneous and sometimes come from sponsored studies. Independent data indicate modest benefits that may be difficult for owners to perceive.
- Plants and botanical extracts (turmeric, devil's claw, CBD…): their anti-inflammatory properties are interesting in the laboratory, but veterinary clinical evidence remains limited or insufficient to make them a reference standard.
These actives are not necessarily useless, but today they do not constitute the best scientifically validated foundation for joint disorders in dogs.
Discover our joint supplement comparison
Marine Omega-3: the most effective supplements according to veterinary science
Conversely, marine Omega-3 fatty acids, in particular EPA and DHA, are the most documented actives with:
- more than 21,000 scientific publications on Omega-3
- nearly 400 veterinary studies in dogs
- and approximately 98 studies specifically on New Zealand green lipped mussel
Discover the best sources of Omega-3
Omega-3s are also the active ingredients with the highest level of evidence in canine joint health.
Two major systematic reviews have shown that Omega-3 are the only dietary supplements with consistently demonstrated effectiveness in arthritic dogs — especially for mobility, pain, and inflammation.
Form matters as much as the ingredient: powder or oil is not equivalent
A point that is often underestimated is the delivery form of the supplement.
Two products can contain the same ingredient… but not be comparable in effectiveness.
This is particularly true for Omega-3:
- Liquid oils provide EPA and DHA in a readily bioavailable form that is well absorbed and generally well tolerated.
- Powders are often much less concentrated and may contain lower levels of active fatty acids.
Green-lipped mussel provides a clear example: its powder contains up to 15 times less Omega-3 than green-lipped mussel oil and takes six times longer to reach peak blood concentration.
Choosing the right source therefore also means choosing the most active form.
Dosage: the most common mistake in joint supplements
Even a well-documented active ingredient may provide limited benefit if the dose is too low.
This is a market reality: many products highlight popular or reassuring ingredients, but at doses too low to reproduce the effects observed in clinical studies.
Owners may conclude that a product does not work when it is simply underdosed or contains quantities too low to reproduce the effects observed in clinical studies.
An effective joint supplement must therefore combine:
- a scientifically validated active ingredient
- a highly assimilable form
- a truly effective dose
- and a formulation designed for results, not just for the label
PERNIXOL® was developed in accordance with these criteria, which is what distinguishes its formulation.
PERNIXOL®: an ultra-concentrated liquid formula that is easy to give
If the previous criteria are applied rigorously, an effective joint supplement must meet three requirements: a validated active, a bioavailable form, and a truly relevant dosage.
This is exactly the approach that guided the development of PERNIXOL®.
PERNIXOL® is a liquid dietary supplement designed to support your dog's long-term mobility. It provides a concentrated source of highly bioavailable marine Omega-3s in a simple formula that is generally well tolerated.
An effective dose in only 1 ml per day
One of the main features that distinguishes PERNIXOL® is its high concentration of active Omega-3s.
Each formula is adapted to the dog's weight and delivers a precise amount of EPA+DHA in only 1 ml:
These dosages were not chosen at random: they are based on the official recommendations of the National Research Council (NRC), the international reference in veterinary nutrition.
The NRC indicates a recommended intake of approximately: 14 mg of EPA + DHA per kg of body weight per day
Consider a practical example: PERNIXOL®70 is intended for dogs weighing less than 10 kg. Using a reference weight of 5 kg, 14 mg × 5 kg equals 70 mg of EPA and DHA per day. That is the concentration provided by 1 ml of PERNIXOL®70.
This approach provides a simple daily dose adapted to the dog's size, without requiring owners to estimate the quantity.
For dogs with diagnosed osteoarthritis or joint disease, a veterinarian may recommend PERNIXOL® alone or alongside treatment. Higher EPA and DHA intakes may be considered without exceeding the NRC maximum of 175 mg per kilogram of body weight per day.
This means that higher therapeutic dosages can be considered under veterinary supervision, while remaining within a well-documented safety margin.
A liquid form that is easy to give and dogs love
A joint supplement is only truly effective if it can be given easily, every day, over the long term. Yet this is often where many products fail: refused tablets, poorly dosed powders, chews too rich in additives…
PERNIXOL® was designed to address these difficulties through a practical, highly bioavailable liquid form that is generally well tolerated.
- The oil-based form naturally improves Omega-3 absorption and limits digestive discomfort.
- The graduated syringe allows precise, quick dosing adapted to the dog's weight.
- PERNIXOL® is also readily accepted by many dogs because of the naturally palatable marine flavour of its ingredients: green-lipped mussel oil and microalgae oil.
With no artificial flavours, colourings or preservatives, daily administration is straightforward and can be maintained consistently over time.
This ease of use is essential, because joint support depends above all on one thing: consistency.
The only liquid supplement rich in green lipped mussel oil
Beyond its Omega-3 concentration, PERNIXOL® stands out above all for the quality and rarity of its ingredients.
Joint supplements differ considerably: many use conventional active ingredients, sometimes in powder form or at low doses.
By contrast, PERNIXOL® is based on a distinctive marine active ingredient that is widely documented in canine joint health: New Zealand green-lipped mussel oil (Perna canaliculus)
Why green lipped mussel oil is superior to powder
Green-lipped mussel is well known in joint support. However, most products use it in powder form, which is much less concentrated than the oil.
Green-lipped mussel oil offers a significantly richer lipid profile:
- up to 15 times more Omega-3 than powder
- presence of rare fatty acids such as ETA and SDA, absent from conventional oils
- • furan fatty acids whose anti-inflammatory activity is described as superior to that of EPA alone
- • powerful antioxidants including carotenoids, capable of eliminating up to 62% of free radicals, with antioxidant activity comparable to that of vitamin C.
This distinctive composition helps explain why green-lipped mussel is one of the most widely studied natural active ingredients for supporting dogs with joint disorders.
It acts on several essential dimensions:
- regulation of inflammation
- cartilage protection
- joint comfort support
- improvement of everyday mobility
Supercritical CO₂ extraction: maximum purity and integrity
But not all green lipped mussel oils are equal. The extraction method is decisive for preserving the quality of fatty acids.
The oil used in PERNIXOL® is extracted by supercritical CO₂, a premium process, solvent-free and without excessive heat.
This process makes it possible to:
- preserve the integrity of sensitive Omega-3
- obtain a very pure, stable and concentrated oil
- maintain consistent quality for prolonged use
PERNIXOL® is currently the only liquid joint supplement rich in green-lipped mussel oil.
To complement its EPA and other specific fatty acids, this oil is combined with a second marine source: fermented microalgae oil, which is particularly rich in DHA.
This combination enables PERNIXOL® to provide a broad spectrum of marine Omega-3s in a highly bioavailable form that supports canine mobility.
A formulation guided by clinical evidence
What distinguishes PERNIXOL® is not a general promise, but the careful selection of marine active ingredients whose effects have been studied in dogs, particularly in canine osteoarthritis and chronic joint disorders.
By relying on reference ingredients such as green lipped mussel oil and Omega-3 EPA and DHA, PERNIXOL® offers a rational, scientific and sustainable approach to canine joint comfort.
Targeted and deep anti-inflammatory action
In canine osteoarthritis, joint inflammation is at the heart of pain, stiffness and loss of mobility.
Unlike conventional oils, the actives selected for PERNIXOL® act directly on the biological pathways involved in chronic inflammation:
- Inhibition of pain mediators
Green lipped mussel oil blocks the production of prostaglandins (PGE2) and leukotrienes (LTB4), involved in joint pain and inflammation (Inflammopharmacology, 1997). - Enzymatic modulation (COX and LOX)
It helps regulate the enzymatic pathways responsible for the inflammatory cascade, while reducing the release of pro-inflammatory cytokines. - The power of furan fatty acids
These lipids specific to green lipped mussel offer anti-inflammatory activity superior to that of EPA alone, enabling an effective response even at low dose.
Superior performance
PERNIXOL® was developed to provide canine joint support through premium marine active ingredients backed by comparative veterinary research.
- Comparative performance
Veterinary research has reported reductions in joint discomfort with green-lipped mussel oil that were comparable to those observed with the anti-inflammatory drug carprofen (Thai Journal of Veterinary Medicine, 2016). - Superior effectiveness to conventional Omega-3 oils
Green-lipped mussel oil showed greater anti-inflammatory activity than standard fish, flax and evening primrose oils at an equivalent dose in the referenced study (Inflammopharmacology, 1997).
Visible results on mobility in arthritic dogs
The effectiveness of a joint supplement is measured above all in daily life: smoother gait, improved weight-bearing, reduced lameness.
Clinical studies on green lipped mussel oil show rapid benefits:
- Improvement in gait and weight-bearing strength from the second week (Veterinary and Comparative Orthopaedics and Traumatology, 2018)
- More than 85% of arthritic dogs showing a marked reduction in lameness in less than one month (Thai Journal of Veterinary Medicine, 2012)
These results support the relevance of PERNIXOL® for supporting the dog's mobility, week after week.
Joint protection: beyond simple relief
A good joint supplement for dogs must not only act on pain, but also support the joint in its structure.
PERNIXOL® is rich in Omega-3 that help slow degradation mechanisms:
- Slowing bone destruction
Green lipped mussel lipids reduce osteoclast activity (cells involved in bone resorption) and decrease the expression of degrading genes such as MMP-9 or cathepsin K (Bone Reports, 2021). - Preserving cartilage thanks to DHA
DHA from fermented microalgae stimulates cellular repair mechanisms and protects subchondral bone, contributing to long-term joint strength (Molecular Medicine, 2023).
In brief, why is PERNIXOL® different?
- Rich in green lipped mussel oil
- Ultra-concentrated in Omega-3 EPA+DHA and natural antioxidants
- Actives clinically validated by veterinary science
- Bioavailable liquid formula that is easy to dose
- Dosage adapted to the dog's weight
- Natural marine taste that dogs love
PERNIXOL® vs other joint supplements
Faced with the multitude of joint supplements available, it is often difficult to understand what truly distinguishes a premium, scientifically grounded product from a more conventional or underdosed formula.
The difference lies not in the messaging, but in objective criteria: evidence supporting the ingredients, their active form and concentration, ease of administration, weight-adapted dosing, side effects and contraindications.
Comparative table of joint supplements for dogs
| Key Criteria | PERNIXOL® | Other Supplements |
|---|---|---|
| Clinically Proven Ingredients | ✓ High | ~ Variable to Moderate. Limited clinical evidence in dogs. |
| Ingredient Concentration | ✓ High | ✗ Low |
| Active Form | ✓ Natural liquid formula | ~ Mostly powders / Low bioavailability |
| Ease of Administration | ✓ Very easy thanks to the graduated dosing syringe and naturally palatable marine taste | ~ Soft chews are easy to give but often contain low active ingredient levels / ✗ Tablets can be difficult to administer |
| Weight-Adapted Dosage | ✓ Three formulas tailored to the dog's body weight | ✗ One-size-fits-all formula requiring owner adjustments |
| Side Effects | ✓ Excellent digestive tolerance with very few reported side effects | ~ Powder-based supplements are often poorly digested |
| Contraindications | ✓ No known contraindications and compatible with all treatments | ✗ May interact with certain medications, and clinical evidence in dogs is often lacking |
PERNIXOL® is therefore not "just another" joint supplement.
It is a distinctive formula in Europe, designed to provide dogs with active Omega-3s, premium green-lipped mussel oil and high bioavailability, with effectiveness supported by the available veterinary evidence.
FAQ
PERNIXOL®, a different choice for lasting mobility
PERNIXOL® is not a joint supplement like the others.
It is a premium marine formula designed to provide effective joint support:
- Ultra-concentrated liquid formula, highly assimilable
- Signature active: green lipped mussel oil extracted by supercritical CO₂
- Complete EPA + DHA synergy, with fermented microalgae
- Effectiveness supported by the best veterinary scientific data
Discover PERNIXOL® for dogs
Scientific references
- Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. Int J Mol Sci. 2022 Sep 8;23(18):10384. doi: 10.3390/ijms231810384.
- Vandeweerd JM, Coisnon C, Clegg P, Cambier C, Pierson A, Hontoir F, Saegerman C, Gustin P, Buczinski S. Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis. J Vet Intern Med. 2012 May-Jun;26(3):448–456.
doi: 10.1111/j.1939-1676.2012.00901.x. - Roberta Cardim Lessa, Belgheis Ebrahimi, Jenn Jury, Mary Sewell, Yiqi Xie, Yan Li, Jun Lu, Characterising bioactive components of green-lipped mussel via two extraction methods: in vitro assessment of antioxidant and immunomodulatory effects, International Journal of Food Science and Technology, Volume 59, Issue 7, July 2024, Pages 4546–4561, doi.org/10.1111/ijfs.17178
- Mongkon N., Soontornvipart K. (2012). Preliminary study of the clinical outcome of using PCSO-524 polyunsaturated fatty acid compound in the treatment of canine osteoarthritis and degenerative spinal diseases. Thai Journal of Veterinary Medicine, 42(3), 311–320.
- Kang K., Kim N., Lim S., Kang B. (2024). Therapeutic effect of green-lipped mussel oil on pain and functional disability in dogs with clinical osteoarthritis. Journal of Veterinary Clinics, 41(6), 350–358. DOI: 10.17555/jvc.2024.41.6.350
- Beale B.S., McLaughlin R.M., et al. (2018). The effectiveness of a marine-based fatty acid compound alone and combined with firocoxib in the treatment of canine osteoarthritis. Veterinary and Comparative Orthopaedics and Traumatology, 31(S 01), A1-A42. DOI: 10.1055/s-0038-1668224
- Kwananocha I., et al. (2016). Effectiveness of disease-modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai Journal of Veterinary Medicine, 46(2), 211–222.
- Siriarchavatana P., et al. (2021). Non-polar lipids from green-shell mussel inhibit osteoclast differentiation and bone resorption. Bone Reports, 15, 101132. DOI: 10.1016/j.bonr.2021.101132
- Whitehouse M.W., et al. (1997). Anti-inflammatory activity of a lipid fraction (Lyprinol®) from the New Zealand green-lipped mussel. Inflammopharmacology, 5(3), 237–246. DOI: 10.1007/s10787-997-0001-6
- Soontornvipart K., et al. (2015). Effect of PCSO-524 on osteoarthritis biomarkers and weight-bearing properties in canine shoulder and coxofemoral osteoarthritis. Thai Journal of Veterinary Medicine, 45(3), 357–366.
- Xie, Y., Zhou, W., et al. (2019). Docosahexaenoic acid inhibits bone remodeling and vessel formation in the osteochondral unit in a rat model of osteoarthritis. Biomedicine & Pharmacotherapy, 118, 109309. DOI: 10.1016/j.biopha.2019.109309
- Wang, Y., Zhao, X., Lotz, M., & Terkeltaub, R. (2023). Docosahexaenoic acid promotes autophagy and attenuates hypertrophic differentiation and senescence of osteoarthritic chondrocytes. Molecular Medicine, 29, 1–14. DOI: 10.1186/s10020-023-00781-3
- Velebný, J., Kopecký, J., Jeníček, V., et al. (2015). Schizochytrium microalga oil reduces body weight, glycaemia and inflammatory markers in rats fed a high-fat diet. Journal of Animal Physiology and Animal Nutrition, 99(4), 711–721. DOI: 10.1111/jpn.12434
- Zhang, L., Terrando, N., et al. (2018). Distinct analgesic actions of DHA and DHA-derived specialized pro-resolving mediators on post-operative pain after bone fracture in mice. Frontiers in Pharmacology, 9, 412. DOI: 10.3389/fphar.2018.00412
This article was written by the R&D team at Laboratoire Sensilia, experts in animal nutrition.
